Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes.

ABSTRACT:

Objective

To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women.

Research design and methods

Forty-one obese women (aged 48 ± 11 years and BMI 33.1 ± 4.1 kg/m(2)) participated in a 35-week randomized, double-blind, placebo-controlled, crossover study, including two 16-week treatment periods separated by a 3-week washout period. There was no lifestyle intervention. The primary outcome was change in body weight.

Results

Subjects treated with exenatide lost an average of 2.49 ± 0.66 kg compared with a 0.43 ± 0.63 kg weight gain during placebo treatment. Weight loss with exenatide treatment was noted at 2 weeks. The degree of weight loss could be stratified. A t

SUBMITTER: Dushay J 

PROVIDER: S-EPMC3241299 | biostudies-literature | 2012 Jan

REPOSITORIES: biostudies-literature